CYTOSORBENTS CORPORATION Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
CYTOSORBENTS CORPORATION (CTSO) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $331.12 thousand for the 12-month period ending 2013-12-31, per its 10-K filed 2015-03-31.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2015-03-31
- CYTOSORBENTS CORPORATION adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2013-12-31 was $0.00.
- CYTOSORBENTS CORPORATION adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2013-09-30 was $142.65K, a 76.13% decline year-over-year.
- CYTOSORBENTS CORPORATION adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2012-12-31 was -$597.51K.
- CYTOSORBENTS CORPORATION adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2012-09-30 was $597.51K.
- CYTOSORBENTS CORPORATION adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2013 was $331.12K, a 277.56% increase from fiscal 2012.
- CYTOSORBENTS CORPORATION adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2012 was $87.70K, a 92.98% decline from fiscal 2011.
- CYTOSORBENTS CORPORATION adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2011 was $1.25M, a 307.42% increase from fiscal 2010.
- CYTOSORBENTS CORPORATION adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2010 was $306.81K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 6 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 9 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|---|---|---|
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | $142.65K derived: sum of 2 quarters · filed 2015-03-31 | $331.12K 10-K · filed 2015-03-31 | |
| 2013-09-30 | $142.65K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | $331.12K 10-Q · filed 2013-11-06 | ||
| 2013-06-30 | $188.47K 10-Q · filed 2013-08-14 | |||
| 2012-12-31 | -$597.51K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-31 | $0.00 derived: sum of 2 quarters · filed 2014-03-31 | $0.00 derived: sum of 3 quarters · filed 2014-03-31 | $87.70K 10-K · filed 2014-03-31 |
| 2012-09-30 | $597.51K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-21 | $597.51K derived: sum of 2 quarters · filed 2012-11-21 | $685.21K 10-Q · filed 2012-11-21 | $685.21K derived: sum of 4 quarters · filed 2014-03-31 |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-13 | $87.70K 10-Q · filed 2012-08-13 | $87.70K derived: sum of 3 quarters · filed 2014-03-31 | $87.70K derived: sum of 4 quarters · filed 2014-03-31 |
| 2012-03-31 | $87.70K 10-Q · filed 2012-05-15 | $87.70K derived: sum of 2 quarters · filed 2014-03-31 | $87.70K derived: sum of 3 quarters · filed 2014-03-31 | |
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-31 | $0.00 derived: sum of 2 quarters · filed 2014-03-31 | $1.25M 10-K · filed 2014-03-31 | |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | $1.25M 10-Q · filed 2011-11-14 | ||
| 2011-06-30 | $1.25M 10-Q · filed 2011-08-15 | |||
| 2010-12-31 | $306.81K 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |